Eisai Co.
 |
|
|
Native name
|
エーザイ株式会社 |
|---|---|
| Public KK | |
| Traded as | : TOPIX 100 Component Nikkei 225 Component |
| Industry | Pharmaceuticals |
| Founded | (December 6, 1941) |
| Founder | Toyoji Naito |
| Headquarters | 4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan |
|
Key people
|
Haruo Naito (President and CEO) |
| Products | |
| Revenue | (JPY 600.4 billion) (FY 2013) |
|
|
|
|
Number of employees
|
10,419 (consolidated, as of March 31, 2014) |
| Website | Official website |
|
Footnotes / references |
|
US$ 320 million (FY 2013)
Eisai Co., Ltd. (エーザイ株式会社 Ēzai Kabushiki-gaisha?) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the and is a member of the Topix 100 and Nikkei 225 .
Nihon Eisai Co. Ltd. was established in 1941. In 1944, merger with Sakuragaoka Research Laboratory resulted in creation of Eisai Co. Ltd. The American subsidiary of the company, Eisai Inc., was established in 1995.
In 1996, Eisai received approval from the United States Food and Drug Administration (USFDA) for Aricept (donepezil), a drug discovered in the company's labs and co-marketed with Pfizer. Three years later in 1999, the company received USFDA approval for Aciphex (rabeprazole), a drug co-marketed with Johnson & Johnson.
...
Wikipedia